Sidley is representing Gamma Biosciences, a life sciences platform established by KKR to address the advanced therapy bioprocessing market, in its US$600 million sale of Mirus Bio to Merck KGaA, Darmstadt, Germany (XTRA:MRK). Mirus Bio is a leading provider of transfection solutions used to deliver genetic material into cells.
The Sidley team is being led by David Zampa and Cameron S. Stanton (M&A and Private Equity), and includes Spencer A. Lee, Will Schoenfeld, Elizabeth Buescher, and Brad I. McGee (M&A and Private Equity); Suresh T. Advani (Tax); Christian E. Pilhofer and Alexandra M. Peterson (Employee Benefits and Executive Compensation); Natalie C. Chan (Labor and Employment); Ash Nagdev and Ernesto R. Claeyssen (Privacy and Cybersecurity); Patrick J. Harrison, James W. Lowe, Laurenz Bové, and Jason C. Semmes (Antitrust and Competition); James Mendenhall and Kayla M. Scott (Trade); and Scott J.F. Goldstein (Insurance).
Sidley also represented Gamma Biosciences when it acquired a controlling stake of Mirus Bio in 2021.
